Omega Therapeutics adds $126M to move “programmable” drugs closer to the clinic

Omega Therapeutics has raised more than $210 million in the past eight months for R&D of medicines that regulate genes. The company’s lead therapeutic candidate addresses a validated but elusive cancer target.